Telomir Pharmaceuticals, Inc.TELO

Telomir Pharmaceuticals Inc. is running a clinical-stage zinc experiment dressed up as a biotech company, and the three-month numbers to 31 March 2026 show a net loss of $990,947 on $34.4 million diluted shares outstanding, an operating loss of $2.2 million in the prior comparable period, and a bank balance that peaked at $754,323 on 30 June 2025. There is no revenue figure in the latest 10-Q, which is probably the clearest sign yet that Telomir is still in the hypothesis-testing business rather than the product-selling one. (source: 10-Q, periods ending 2026-03-31 and 2025-06-30, https://www.sec.gov/Archives/edgar/data/1971532/000169104026002070/0001691040-26-002070-index.htm)

The company’s pipeline is anchored on Telomir-Zn, a zinc-based small molecule whose most publicised milestones are an FDA Investigational New Drug clearance for a triple-negative breast cancer trial and a preclinical Type-2 diabetes paper in Biomedicine & Pharmacotherapy. Neither is a revenue generator. The IND is a gate-opener, not an approval; the peer-reviewed paper is a data point, not a drug. The product pages and slide decks are visually polished, but the capital structure is not: Telomir’s 8-K on 15 June 2026 authorised a $2.5 million private placement at $0.07 per share, a price that dilutes existing holders and hands new capital to a company whose total assets are $5.8 million and whose liabilities are $827,310. (source: Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer, https://ir.telomirpharma.com/news-events/press-releases/telomir-pharmaceuticals-announces-fda-clearance-of-ind-for-telomir-zn-in-triple-negative-breast-cancer; TELO 8-K (2026-06-15), https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/form8-k.htm)

Financially, Telomir’s position is that of a pre-revenue zinc hypothesis generator: net cash used in operating activities was $1.8 million in the quarter, research and development spend was $467,797, and the diluted loss per share was $0.03. Total shareholders’ equity is $5.0 million, so the equity cushion is thin relative to the dilution that has already occurred and the $2.5 million placement that has just been approved. Guidance is absent; the company does not forecast revenue or cash runway in its filings. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1971532/000169104026002070/0001691040-26-002070-index.htm)

The stock trades on the OTCQB under the symbol TELO, where liquidity is thin and spreads can widen faster than a zinc ion in dilute acid. The company points investors to its investor email alerts page and its research portal, but neither page lists intraday trading data, volumes, or a liquidity depth-of-book. If the source requires readers to see the instrument before you decide whether to hold, the chart route is OTCQB:TELO on TradingView, where the candles are plentiful but the order book is not. (source: Official product/news rail, https://ir.telomirpharma.com/investors-email-alerts/; TradingView route OTCQB:TELO, https://www.tradingview.com/symbols/OTCQB-telo/)

What changed in the last month: the company used the SEC’s XML submissions feed to update its share count and ownership structure on 8 July 2026, confirming that the $2.5 million placement at $0.07 per share is proceeding and will increase the diluted share base materially above the 34.4 million units reported in the 10-Q. The SEC’s company facts JSON still does not contain any revenue line items, so the revenue story remains unwritten. (source: SEC submissions JSON feed, https://data.sec.gov/submissions/CIK0001971532.json; SEC company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001971532.json)

What we do not know: Telomir has not filed a revenue line in any SEC document accessible via EDGAR since inception; it has not provided cash runway, R&D burn rate beyond the quarterly line, or any segment-level breakdowns. The research portal shows pipeline diagrams and microscopy slides, but those images prove only that experiments exist, not that they will succeed. (source: SEC EDGAR filing index for CIK 1971532, https://www.sec.gov/edgar/browse/?CIK=1971532)

What would change the file next: Telomir would become materially less speculative if it disclosed any revenue, guidance, or a contracted supply agreement; if it published Phase 2 data for Telomir-Zn in either indication; or if it secured a non-dilutive financing such as a grant or partnership. Until then, the zinc hypothesis remains untested in the revenue column and the equity cushion remains thin. (source: SEC EDGAR index and company facts JSON, https://www.sec.gov/edgar/browse/?CIK=1971532; https://data.sec.gov/api/xbrl/companyfacts/CIK0001971532.json)